Alberto Espay, MD, MSc, University of Cincinnati, Cincinnati, OH, comments on the results from two recent clinical trials evaluating anti-α-synuclein immunotherapy approaches for the treatment of Parkinson's disease. Both trials included agents targeting the aggregated form of α-synuclein, and while the trials were supported by robust evidence, the outcomes of both were negative, contradicting the results hypothesized. Therefore, it is essential to rethink the relationship between α-synuclein and disease; perhaps focus on the loss of normal proteins rather than the abnormal aggregation, and shift towards the replacement of α-synuclein instead of the anti-α-synuclein approach. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
13 ноя 2022
